Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAHN phase 3 long-term efficacy and safety study of baricitinib in adults with atopic dermatitis
MOH_2017-11-13_000858Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (4 arms), sponsored by Eli Lilly and Company. Started Oct 2017; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2017-11-13_000858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-13_000858.